BioCentury
ARTICLE | Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

May 18, 2018 2:11 PM UTC

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a Phase II trial to treat metastatic castration-resistant prostate cancer (CRPC). The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

177Lu-PSMA-617 is a prostate-specific membrane antigen (PSMA; FOLH1; GCPII) directed radioligand therapy...